Table 1 Baseline characteristics

Gender

63M/15F

49M/13F

14M/2F

0.72

Age at referral

66, 43–87

64, 43–87

71, 55–84

0.14

Beta-adrenoceptor antagonists

57

45

12

1.00

Ca²⁺-channel antagonists

35

24

11

< 0.05

Long-lasting nitrates

58

45

15

0.10

Warfarin

6

4

2

0.60

Aspirin

67

53

14

1.00

ACEI or ARB

36

26

10

0.17

Diuretics

27

19

8

0.24

Lipid lowering agents

64

50

14

0.72

Insulin

11

7

4

0.22

Oral antidiabetics

8

3

5

< 0.01

Diabetes

16

9

7

< 0.02

Hypertension

26

19

7

0.38

Atrial fibrillation

3

2

1

0.50

Current smoker

3

3

0

1.00

Myocardial infarction

47

38

9

0.78

CABG

57

44

13

0.54

PCI

45

37

8

0.57

CABG or PCI

66

51

15

0.44

Pacemaker

6

3

3

0.10

CCS IV

12

10

2

0.46

CCS III

58

47

11

CCS II

8

5

3

CCS I

0

0

0

Years with CAD

11.5, 1–35

11.5, 1–35

11, 2–33

0.98

EF > 50%

48

39

9

0.76

EF 50 – 41%

14

10

4

EF 40 – 30%

14

11

3

EF < 30%

2

2

0